Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

Fig. 7

h1219-CART19 phase I clinical trial CAR T expansion, blood cell counts, and serum cytokine levels. A AT101 expansion and persistence in the blood detected by qPCR in DL-1, DL-2 and DL-3. B Mean serum levels of sFas ligand, granzyme A, or perforin across 12 patients over time by Luminex. C AT101 expansion in complete response patients (n = 9) and not complete response patients (n = 3) by qPCR. D B cell count in complete response patients (n = 9) and not complete response patients (n = 3). E (Left) sFas ligand and (right) serum amyloid A levels on day 1 pre AT101 infusion and days 2–168 post AT101 infusion in complete response patients and not-complete response patients by Luminex. F IP-10 serum level change over time in patients without CRS (n = 8) and patients with CRS (n = 4) by Luminex. G Platelet level change over time in patients without CRS (n = 8) and patients with CRS (n = 4) by Luminex. H Ferritin level change over time in patients without CRS (n = 8) and patients with CRS (n = 4)

Back to article page

Molecular Cancer

ISSN: 1476-4598